CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic ...
At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on using resmetirom (Rezdiffra) and semaglutide (Ozempic, Wegovy) for metabolic ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Resmetirom maintained meaningful improvements in MASH ...
Please provide your email address to receive an email when new articles are posted on . In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering ...
Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Resmetirom ...
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in ...
After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to market to treat the liver disease non-alcoholic ...
WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results